Company / Capital Expenditures
Edgewise Therapeutics, Inc. Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$256.0K
FY2025
5-year range
$256.0K / $5.7M
FY2021-FY2025
Trend
-80.5%
vs FY2024
Sector context
#152 of 194
Health Care
What the data says
Edgewise Therapeutics, Inc.'s capital expenditures of $256,000 is lower than 78% of companies in the Health Care sector (FY2025). Declined from $6M to $256,000 over the past 2 years.
Based on SEC 10-K filings.
$256,000 in FY2025 with a 5-year CAGR of +4.7%.
Declined from $6M to $256,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -64.1%
- 5-Year CAGR
- +4.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 194This company $256.0K Sector average $117.5M
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.7%, indicating consistent growth.
- In FY2025, capital expenditures decreased 80.5% year-over-year.
- Ranks #152 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $256.0K | -80.5% |
| FY2024 | $1.3M | -77.2% |
| FY2023 | $5.7M | +3.6% |
| FY2022 | $5.5M | +730.2% |
| FY2021 | $668.0K | +229.1% |
| FY2020 | $203.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026